Categories
Topics

Parithera, an EPFL spin-off, has developed a system that lets doctors detect drug resistance in cancer patients early on, saving precious time and preventing the unnecessary use of treatments with onerous side effects.

Parithera, an EPFL spin-off, has developed a system that lets doctors detect drug resistance in cancer patients early on, saving precious time and preventing the unnecessary use of treatments with onerous side effects. Antoine Herzog, CEO of Parithera and his prototype.

Media properties

Themes
Research and Tech Transfer , Cancer, Startups and Industry, Research and Tech Transfer
Copyright
EPFL - Alain Herzog
Licence
CC0 Licence
Shooting date
Oct. 6, 2023
Album
Rapid early detection of drug resistance in cancer patients

Share on